Matrix metalloproteinase 2-responsive micelle for siRNA delivery

Biomaterials

Volumn 35, Issue 26, 2014, Pages 7622-7634

  Wang, Hong Xia ^a   Yang, Xian Zhu ^a   Sun, Chun Yang ^a   Mao, Cheng Qiong ^a   Zhu, Yan Hua ^a   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cancer therapy; Matrix metalloproteinase 2 responsiveness; Micelleplex; Polo like kinase 1; SiRNA delivery

Indexed keywords

BLOOD; CELLS; ENZYMES; MICELLES; ONCOLOGY; PEPTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS;

CANCER THERAPY; MATRIX METALLOPROTEINASE-2; MICELLEPLEX; POLO-LIKE KINASE 1; SIRNA DELIVERY;

RNA;

ANTINEOPLASTIC AGENT; COPOLYMER; GELATINASE A; MACROGOL; MICELLEPLEX; NANOPARTICLE; POLO LIKE KINASE 1; POLYARGININE; POLYCAPROLACTONE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; ONCOPROTEIN; PEPTIDE; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CHEMICAL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG UPTAKE; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICELLE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; ZETA POTENTIAL; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUDE MOUSE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HEK293 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE, INBRED BALB C; MICE, NUDE; MICELLES; MOLECULAR SEQUENCE DATA; PEPTIDES; POLYETHYLENE GLYCOLS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84902551145     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.050     Document Type: Article

References (47)

1. Davidson B.L., McCray P.B. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011, 12:329-340.
2. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012, 19:60-71.
3. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003, 100:183-188.
4. Ashley C.E., Carnes E.C., Phillips G.K., Durfee P.N., Buley M.D., Lino C.A., et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 2011, 5:5729-5745.
5. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
6. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176.
7. Schroeder A., Levins C.G., Cortez C., Langer R., Anderson D.G. Lipid-based nanotherapeutics for siRNA delivery. JIntern Med 2010, 267:9-21.
8. Huang L., Liu Y. Invivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011, 13:507-530.
9. Dou S., Yao Y.D., Yang X.Z., Sun T.M., Mao C.Q., Song E.W., et al. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. JControl Release 2012, 161:875-883.
10. Yao Y.D., Sun T.M., Huang S., Dou S., Lin L., Chen J., et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 2012, 4:130-148.
11. Ashley C.E., Carnes E.C., Epler K.E., Padilla D.P., Phillips G.K., Castillo R.E., et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 2012, 6:2174-2188.
12. Liu J., Wang B., Hartono S.B., Liu T., Kantharidis P., Middelberg A.P., et al. Magnetic silica spheres with large nanopores for nucleic acid adsorption and cellular uptake. Biomaterials 2012, 33:970-978.
13. Qian X.M., Long L.X., Shi Z.D., Liu C.Y., Qiu M.Z., Sheng J., et al. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. Biomaterials 2014, 35:2322-2335.
14. Zhou J., Patel T.R., Fu M., Bertram J.P., Saltzman W.M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012, 33:583-591.
15. Gao L.Y., Liu X.Y., Chen C.J., Wang J.C., Feng Q., Yu M.Z., et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for invivo siRNA delivery. Biomaterials 2014, 35:2066-2078.
16. Li X., Chen Y.J., Wang M.Q., Ma Y.J., Xia W.L., Gu H.C. Amesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013, 34:1391-1401.
17. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010, 49:6288-6308.
18. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
19. Song L.Y., Ahkong Q.F., Rong Q., Wang Z., Ansell S., Hope M.J., et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta 2002, 1558:1-13.
20. Mishra S., Webster P., Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 2004, 83:97-111.
21. Pan Y.J., Chen Y.Y., Wang D.R., Wei C., Guo J., Lu D.R., et al. Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release. Biomaterials 2012, 33:6570-6579.
22. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. JAm Chem Soc 2011, 133:17560-17563.
23. Kim S.W., Kim N.Y., Choi Y.B., Park S.H., Yang J.M., Shin S. RNA interference invitro and invivo using an arginine peptide/siRNA complex system. JControl Release 2010, 143:335-343.
24. Kim T.I., Ou M., Lee M., Kim S.W. Arginine-grafted bioreducible poly (disulfide amine) for gene delivery systems. Biomaterials 2009, 30:658-664.
25. Li H., Yu S.S., Miteva M., Nelson C.E., Werfel T., Giorgio T.D., et al. Matrix metalloproteinase responsive, proximity-activated polymeric nanoparticles for siRNA delivery. Adv Funct Mater 2013, 23:3040-3052.
26. Zhu L., Kate P., Torchilin V.P. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6:3491-3498.
27. Hatakeyama H., Akita H., Ito E., Hayashi Y., Oishi M., Nagasaki Y., et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 2011, 32:4306-4316.
28. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
29. Jiang T., Olson E.S., Nguyen Q.T., Roy M., Jennings P.A., Tsien R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004, 101:17867-17872.
30. Huang S., Shao K., Kuang Y., Liu Y., Li J., An S., et al. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials 2013, 34:5294-5302.
31. Yang X.Z., Du J.Z., Dou S., Mao C.Q., Long H.Y., Wang J. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 2011, 6:771-781.
32. Wang H.X., Xiong M.H., Wang Y.C., Zhu J., Wang J. N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver. JControl Release 2013, 166:106-114.
33. Liu X.Q., Sun C.Y., Yang X.Z., Wang J. Polymeric-micelle-based nanomedicine for siRNA delivery. Part Part Syst Charact 2013, 30:211-228.
34. Yuan Y.Y., Mao C.Q., Du X.J., Du J.Z., Wang F., Wang J. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor. Adv Mater 2012, 24:5476-5480.
35. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
36. Awasthi V.D., Garcia D., Goins B.A., Phillips W.T. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm 2003, 253:121-132.
37. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
38. 15) triblock copolymer for siRNA delivery. Biomaterials 2012, 33:6793-6807.
39. Won Y.W., Yoon S.M., Lee K.M., Kim Y.H. Poly (oligo-d-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. Mol Ther 2011, 19:372-380.
40. Brown S., Bernardo M.M., Li Z.H., Kotra L.P., Tanaka Y., Fridman R., et al. Potent and selective mechanism-based inhibition of gelatinases. JAm Chem Soc 2000, 122:6799-6800.
41. Slepushkin V.A., Simoes S., Dazin P., Newman M.S., Guo L.S., de Lima M.C.P., et al. Sterically stabilized pH-sensitive liposomes intracellular delivery of aqueous contents and prolonged circulation invivo. JBiol Chem 1997, 272:2382-2388.
42. Mao C.Q., Du J.Z., Sun T.M., Yao Y.D., Zhang P.Z., Song E.W., et al. Abiodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials 2011, 32:3124-3133.
43. Sato H., Kida Y., Mai M., Endo Y., Sasaki T., Tanaka J., et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992, 7:77-83.
44. Hatakeyama H., Akita H., Kogure K., Oishi M., Nagasaki Y., Kihira Y., et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther 2006, 14:68-77.
45. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. JClin Invest 2009, 119:661-673.
46. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994, 54:987-992.
47. Poon Z., Chang D., Zhao X., Hammond P.T. Layer-by-layer nanoparticles with a pH-sheddable layer for invivo targeting of tumor hypoxia. ACS Nano 2011, 5:4284-4292.